Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

ALSUntangled does not recommend ursodiol for ALS at 300 mg twice daily

Original source

TUDCAALSUntangled · 27 June 2014

ALSUntangled concluded that ursodiol at 300 mg twice daily was no better than placebo at prolonging survival or slowing ALS progression. It does not recommend off-label use of ursodiol for ALS at this dose.

Why this matters

This means the reviewed evidence does not support using ursodiol 300 mg twice daily as an ALS treatment. Whether higher doses or different formulations might help remains unknown and would require well-designed studies.

Limitations and context

This is an expert review published in 2014, not a new clinical trial. The review also described anecdotal reports and a poorly designed study with many drop-outs; those findings are weaker than the analysis from the randomized, double-blind ceftriaxone trial. The conclusion applies to the reviewed dose, and evidence for higher doses or other formulations was not established.

Relevant to you?